Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation
Status:
Completed
Trial end date:
2020-02-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of risankizumab compared to
placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian
Federation.